7 Biotech Stocks With FDA Catalysts: Ranked by Risk-Reward

Biotech investing in H2 2026 is a target-rich environment. The FDA review calendar is packed with PDUFA dates through December, and if you know how to read a PDUFA date, you can position ahead of binary events that move stocks 20 to 50 percent in a single session.

Seven stocks with confirmed FDA catalysts in the next six months, ranked by risk-reward rather than market cap. Each pick has a specific PDUFA date, clinical trial data, and a number behind the thesis. Two of these are explicit avoid calls. If you want the broader Q3 FDA calendar, we track every date there.

1. Cogent Biosciences (COGT) | $40.67 | Market Cap $6.9B | PDUFA Nov 30 and Dec 30

Cogent has two bezuclastinib PDUFA dates: November 30 for GIST in combination with sunitinib (Priority Review), and December 30 for non-advanced systemic mastocytosis as monotherapy. The SUMMIT trial hit its primary endpoint hard: total symptom score improved 43 percent on bezuclastinib versus 29 percent on placebo (p<0.001). Thirty-four percent of treated patients achieved a 50 percent or greater TSS reduction versus 18 percent on placebo (p=0.01). Biomarkers were even cleaner: 87.4 percent achieved a 50 percent or greater reduction in serum tryptase.

The comp is Blueprint Medicines, which got avapritinib approved for advanced systemic mastocytosis. Cogent is targeting non-advanced SM, a population roughly 5x larger than the advanced form, where no drug is specifically approved. Bezuclastinib also carries FDA Breakthrough Therapy designation for GIST, where it would be the first new therapy in over 20 years. Cogent ranks first because the clinical data hit p<0.001 on primary and secondary endpoints, and the market is under-pricing the NonAdvSM opportunity at $6.9B. We previously covered the GIST PDUFA in depth.

2. Ultragenyx (RARE) | $25.98 | Market Cap $2.6B | PDUFA Sept 19

UX111 is an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), a fatal neurodegenerative disease with a median life expectancy of 15 years and 3,000 to 5,000 patients in commercially accessible markets. The Transpher A study showed a 23.2-point treatment effect on Bayley-III cognitive scores versus natural history (p<0.0001) in children treated before age two. CSF heparan sulfate dropped a median 64 percent (p<0.001). These are not marginal numbers.

At $2.6B market cap, RARE is pricing in meaningful approval odds. The comp is Sarepta at $1.68B, which has $731M in quarterly revenue and multiple approved products. RARE has zero revenue and one BLA under review. But UX111 would be the first therapy for Sanfilippo, and orphan drug pricing in ultra-rare disease routinely exceeds $2M per patient. If approved, the stock re-rates to the upside. If the FDA issues a second CRL, the stock loses 40 percent. We covered the UX111 PDUFA analysis earlier.

3. Ionis Pharmaceuticals (IONS) | $55.30 | Market Cap $9.2B | PDUFA Sept 22

Zilganersen is an antisense oligonucleotide that reduces overproduction of glial fibrillary acidic protein, the underlying cause of Alexander disease. If approved, it would be the first disease-modifying therapy for a condition that affects roughly 1 in 1 to 3 million people worldwide. The FDA granted Priority Review with a September 22 PDUFA.

At $9.2B market cap, Ionis is the largest company on this list, and the stock will not double on a zilganersen approval. The drug targets an ultra-rare population. But Ionis has a deep pipeline of antisense assets, and each approval validates the platform. The comp is Alnylam at roughly $30B market cap with over $2B in annual revenue. Ionis at $9.2B with over $1B in annual revenue trades at roughly 7x revenue; Alnylam trades at 15x. The zilganersen PDUFA could start closing that valuation gap.

4. Savara (SVRA) | $5.33 | Market Cap $1.1B | PDUFA Nov 22 (extended)

MOLBREEVI (molgramostim) is an inhaled GM-CSF for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved therapies in the US or Europe. The FDA extended the PDUFA from August 22 to November 22 after classifying Savara’s responses to information requests as a major amendment. The agency explicitly cited no safety, efficacy, or manufacturing concerns. This is an administrative extension, not a scientific red flag.

At $1.1B market cap, SVRA is a pure play on this single catalyst. First-in-class therapies for rare respiratory diseases have a strong approval track record when the FDA acknowledges the data package is sufficient. The risk is that the FDA convenes an advisory committee and raises questions about the clinical meaningfulness of pulmonary gas transfer improvements. The reward is that approval makes this a $2 to $3B company overnight. We track rare disease catalysts in our rare disease stocks roundup.

5. Sarepta Therapeutics (SRPT) | $15.43 | Market Cap $1.68B | Contrarian Pick

This is the stock the market hates. ELEVIDYS revenue declined to $102M in Q1 2026 from $110M in Q4 2025. The FDA forced a black box warning for acute liver injury. The company cut 36 percent of its workforce, roughly 500 employees, to save $400M annually. CEO Doug Ingram was replaced by Michael Severino effective July 28.

Here is the contrarian thesis. Sarepta generated $731M in total Q1 2026 revenue. The market cap is $1.68B. That is a price-to-sales ratio under 0.6 on an annualized basis, for a company with multiple approved Duchenne products and a gene therapy on the market. The restructuring is painful but necessary. Severino ran Vertex’s commercial engine and is a proven operator. If he stabilizes ELEVIDYS and advances the siRNA pipeline, this stock doubles from a low base. The Severino appointment was the first step.

The risk is real: ELEVIDYS could lose the non-ambulant population entirely if the enhanced immunosuppression protocol fails to satisfy the FDA. But at $1.68B, you are paying less than 0.6x revenue for a franchise that generated nearly $3B annualized. The market is pricing in failure. The market is wrong.

6. Replimune (REPL) | $5.35 | Market Cap $724M | PDUFA Aug 2 (imminent)

The AdCom is July 30. The PDUFA is August 2. The stock dropped 19 percent on July 28 on 24 million shares, versus a typical 3 million. The FDA briefing documents spooked the market.

Replimune has submitted the same BLA three times. The FDA issued two complete response letters, in July 2025 and April 2026. The IGNYTE trial showed a 32.9 percent objective response rate with a 15 percent complete response rate in advanced melanoma patients who progressed on anti-PD-1 therapy. The median duration of response was 24.8 months, and 44.8 percent of responders maintained response at 3 years.

Those durability numbers are genuinely impressive. But a 33 percent ORR is modest for a third-line melanoma population, and the FDA has already rejected this data twice. New FDA leadership signaled a more collaborative posture, which is why the third resubmission got accepted with an expedited review. This is a coin flip. We covered the RP1 PDUFA and AdCom in our breaking coverage. The stock is cheap at $724M if approved, but the binary risk is extreme. Buy only if you can stomach a total loss.

7. GSK (GSK) | Avoid | PDUFA Nov 27 (neladalkib)

GSK completed its $10.6B acquisition of Nuvalent in July 2026. Zidesamtinib was approved by the FDA on July 22 for ROS1-positive NSCLC. The next catalyst is neladalkib, an ALK-selective inhibitor with a PDUFA of November 27 for TKI pre-treated ALK-positive NSCLC.

This is the avoid call. GSK is a mega-cap pharmaceutical company with a market cap north of $80B. Neladalkib’s peak sales estimate is $1 to $2B annually. Even at the high end, that is under 3 percent of GSK’s revenue base. The stock will not move on this PDUFA. If you want to play the oncology catalyst, GSK is the wrong vehicle. The oncology catalysts roundup has better pure plays. The drugs are good; the stock is uninvestable for catalyst-driven returns.

The Risks

Every stock on this list faces binary FDA risk. A complete response letter erases 30 to 50 percent of market cap in a single session. Cogent’s data hit p<0.001 on primary and secondary endpoints, but two PDUFA dates means two binary events. RARE is a gene therapy, and the FDA has been unpredictable on gene therapy approvals. SVRA’s three-month extension could signal deeper review concerns despite the agency’s reassurances. REPL has already failed twice and is a coin flip at best.

Top 3

1. COGT: p<0.001 data on primary and secondary endpoints, two shots on goal, underpriced NonAdvSM market. Buy for the catalyst and hold for the franchise.
2. RARE: first-in-disease gene therapy with p<0.0001 cognitive data. High risk, high reward at $2.6B.
3. SRPT: contrarian. Less than 0.6x revenue with a proven DMD franchise and a new CEO. The market is pricing in catastrophe.

Avoid GSK for catalyst investing. Trade REPL only if you can tolerate a total loss. For more on how to approach biotech investing, start with our guide to investing in biotech.